Valsartan Stada 160mg treatment for hypertension, heart failure (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Valsartan

Ingredient

Composition information	Content
Valsartan	160mg

Uses

Indications

Valsartan Stada® 160 mg is indicated in the following cases:

Indications for treatment of hypertension, reducing cardiovascular mortality on patients with left ventricular failure after heart attack and is used to treat heart failure. Valsartan prevents the physiological effects of Angiotensin II including vascular contraction and secretion effects, by selecting Angiotensin II cohesion into the AT1 receptor in many tissues such as blood vessel muscles and adrenal glands. When compared, the enzyme inhibitors transferred Angiotensin (ACE, Kinase II) to prevent the conversion of angiotensin I into angiotensin II; However, the prevention of the formation of Angiotensin II by inhibiting ACE is not entirely because the hormone causes this vasoconstrictor can be formed through other enzymes that ACE inhibitors are not blocked.

Because Valsartan is not like the enzyme inhibitors, does not inhibit ACE, the drug does not hinder the response to Bradykinin and P; An effective result is that there is no side effects caused by ACE inhibitors (such as dry cough), but the effect on the kidneys and/or protect the heart may not be equal. Valsartan also does not interfere with the synthesis of angiotensin II.

Dynamic pharmacokinetics

Valsartan are quickly absorbed after drinking with bioavailability about 23%. The peak concentration of Valsartan in plasma is reached 2-4 hours after a dose. 94 - 97% of the drug associated with plasma proteins. Valsartan is insignificant metabolized and is excreted mainly through the honey in a constant form. The sale time is about 5 - 9 hours. After drinking, about 83% of the drug is eliminated in feces and 13% in urine.

Before taking Valsartan Stada 160mg treatment for hypertension, heart failure (3 blisters x 10 tablets)

How to use

Valsartan Stada is used orally, regardless of meals.

Dosage

Hypertension

Valsartan is used at the starting dose of 80 mg x 1 time/day. The dose may be increased to 160 mg x 1 time/day if necessary, but the dose is up to 320 mg x 1 time/day. The starting dose is lower than 40 mg x 1 time/day for people over 75 years of age, and people reduce the inner volume; Recommended reduction of dose on liver failure or kidney failure.

heart failure

The starting dose of valsartan 40 mg x 2 times/day. When tolerated, the dose should be increased to 160 mg x 2 times/day.

after myocardial infarction

Valsartan may start early 12 hours after myocardial infarction in patients with stable clinical patients, the dose starts 20 mg twice a day, can double the dose in the next few weeks to 160 mg x 2 times/day if tolerated.

Hepatic failure

Maximum dose of 80 mg x 2 times/day is recommended for patients with liver failure.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when using overdose?

Overdose data in humans is limited. The most common expression of overdose is hypotension and tachycardia; It is also possible to occur slowly due to sympathetic nerve stimulation (vagus nerves). Reducing the level of awareness, circulation and shock were reported.

Handling

If symptomic hypotension occurs, it is necessary to conduct supportive treatment. Valsartan is not excluded through hemorrhage.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using Valsartan Stada® 160 mg, you may experience unwanted effects (ADR).

Unknown frequency, ADR> 1/100

Cardiovascular: Hypotension with dizziness.

Metabolism: hyperkalemia.

Hematology: Anemia, neutropenia, thrombocytopenia, nosebleeds. digestive: diarrhea, taste disorders.

Body: fainting, fatigue, dry cough, headache.

musculoskeletal: joint pain, muscle pain. immune: Sensitive reactions (such as rash, itching, vasculitis and serum disease).

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

Valsartan Stada® 160 mg contraindicated in the following cases:

Patients with hypersensitivity to Valsartan or any ingredients of the drug.

Pregnant women.

Be cautious when using

in patients with salt loss and/or severe loss of epidemic, as those who are taking high doses of diuretics, lowering blood pressure may occur in some rare cases after the beginning of treatment with valsartan.

Renal artery stenosis

Use Valsartan in a short time for patients with secondary kidney hypertension due to kidney stenosis on the one side does not cause any significant changes in kinetic hemodynamics, serum, or blood urea (bun). However, because other drugs affect the Renin - Angiotensin - Aldosteron system can increase serum blood urea and creatinine in patients with kidney stenosis on both sides or one side, so it is necessary to monitor as a safe measure.

Hepatic failure

According to pharmacokinetic data, the plasma valsartan concentration increases significantly on patients with mild to medium liver failure, recommending lower doses in hypertension patients.

Renal function

As a result of inhibition of the Renin - Angiotensin - Aldosteron system, the condition of increased blood urea and serum creatinine and renal function changes including kidney failure (very rare) have been reported specifically in patients with previous kidney function or patients with severe heart failure. Serum potassium concentration should be monitored in patients with renal failure or on the elderly if they are taking potassium supplements.

Patients after myocardial infarction

As a result of inhibition of the Renin - Angiotensin - Aldosteron system, the change in renal function can be anticipated in sensitive individuals. Evaluation of patients after myocardial infarction must always include kidney function assessment.

The ability to drive and operate machinery

No data mentioned about the effects of Valsartan on the ability to drive and operate machinery. When driving or operating machinery, it should be noted that occasionally dizziness or fatigue may occur during treatment with any hypertension.

Pregnancy

Medicines directly acting on the Renin - Angiotensin system that is likely to cause damage and death for the fetus and infants when used for pregnant women. If you find pregnancy, you should stop using Valsartan as soon as possible.

The period of breastfeeding

is not sure whether Valsartan will be excreted through breast milk, but Valsartan is excreted through breastfeeding mice. Due to the ability to cause side effects in breastfeeding children, it is recommended to stop breastfeeding or stop taking the drug after considering the importance of the drug for the mother.

Drug interaction

has not seen clinical interactions when Valsartan combined with amlodipin, Atenolol, cimetidine, digoxin, furosemid, glyburric, hydrochlorothiazid or indomethacin. The combination of Valsartan and Atenolol increases the anti -hypertension effect rather than used individually, but the heart rate reduction effect is not equal to only using alone atenolol.

Combining Valsartan with Warfarin does not change Valsartan's pharmacokinetics or Warfarin's anticoagulant time.

Interacting with CYP450: The enzyme is not responsible for transforming Valsartan but not the IZYM of CYP450. It is unclear the ability to inhibit or induction of Valsartan to CYP450.

As well as other blockers or other impact on Angiotensin II, used in combination with potassium -saving diuretic (such as Spironolacton, Triamteren, Amilorid), Potassium supplements or salt -containing salt -containing potassium drugs that can lead to increased serum potassium levels and on heart failure patients can increase serum creatinine levels.

Storage

In closed packaging, dry place. The temperature does not exceed 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.